Akebia Therapeutics, Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AKBA Company Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
AKBA Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AKBA Smart Score
Score Breakdown
AKBA Company Description
Show More
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AKBA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AKBA's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on AKBA's company Twitter account
WallStreetBets
Number of mentions of AKBA in WallStreetBets Daily Discussion
AKBA News
Recent insights relating to AKBA
CNBC Recommendations
Recent picks made for AKBA stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AKBA
Corporate Flights
Flights by private jets registered to AKBA
Our Analysis